{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:47:21Z","timestamp":1791798441183,"version":"4.3.4"},"reference-count":57,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Achieving durable prolactinoma remission while preserving safe pregnancy remains a central unmet goal of cabergoline therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To prospectively evaluate individualized-dose cabergoline therapy for safe pregnancy, remission, and dosing optimization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women with 310 prolactinomas comprised 97 bromocriptine (Bc)-resistant, 93 Bc-intolerant, and 120 na\u00efve patients, harboring 56 large macroprolactinomas (\u226520\u2005mm), 80 small macroprolactinomas (\u226510\u2005mm), and 174 microprolactinomas. Cabergoline dosing was individualized to maintain nadir prolactin within the lowest achievable normal range. In 129 macroprolactinomas and 19 microprolactinomas at risk of gestational enlargement, medical debulking prophylactically restored the optic\u2013pituitary (O\u2013P) distance to &amp;gt;5.0\u2005mm before conception. Cabergoline was discontinued immediately after conception.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment achieved 100% biochemical normalization; 84-100% prepregnancy tumor debulking; 365 uneventful pregnancies in 294 patients (95%); no symptomatic tumor enlargement during pregnancy; and 72% postpartum remission overall (na\u00efve 82%, Bc-resistant 70%, Bc-intolerant 61%; microprolactinomas 73%, macroprolactinomas 72%). Responder frequency was subtype-specific across 0.25-9.0\u2005mg\/week doses with distinct ED50 values ranging from 0.66 in Bc-intolerant to 3.71 in Bc-resistant patients. AIC-based multivariate analysis identified nadir prolactin\u2014markedly lower in nonvisible than residual prolactinomas\u2014as the dominant determinant of tumor disappearance. No cardiac valvulopathy or impulse control disorders were observed on longitudinal follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite marked ED50 heterogeneity, nadir prolactin-guided individualized-dose cabergoline therapy safely achieved durable remission with excellent pregnancy outcomes. These findings establish a clinically actionable, outcome-directed framework that prospectively integrates endocrine normalization, anatomical risk reduction, and tumor eradication, rendering durable remission and safe pregnancy realistically achievable therapeutic objectives in prolactinomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag406","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:57:06Z","timestamp":1790769426000},"source":"Crossref","is-referenced-by-count":0,"title":["Nadir prolactin-guided individualized cabergoline therapy achieves durable remission and safe pregnancy in prolactinomas"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0050-0905","authenticated-orcid":false,"given":"Nobuhiro","family":"Miki","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tokyo Clinic , Tokyo 100-0004 ,","place":["Japan"]},{"name":"Department of Endocrinology and Metabolism, Tokyo General Hospital , Tokyo 165-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-5643","authenticated-orcid":false,"given":"Masami","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Tokyo Clinic , Tokyo 100-0004 ,","place":["Japan"]},{"name":"Department of Endocrinology and Metabolism, Tokyo General Hospital , Tokyo 165-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-8066","authenticated-orcid":false,"given":"Shun-ichiro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Tokai University School of Medicine , Kanagawa 259-1193 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-896X","authenticated-orcid":false,"given":"Tomokatsu","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Moriyama Neurological Center Hospital , Tokyo 134-0088 ,","place":["Japan"]},{"name":"Department of Neurosurgery, Tokyo Clinic , Tokyo 100-0004 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Nuclear Medicine, Tokyo Women\u2019s Medical University , Tokyo 162-8666 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-7065","authenticated-orcid":false,"given":"Takakazu","family":"Kawamata","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tokyo Women\u2019s Medical University , Tokyo 162-8666 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"2","key":"2026101205065799800_dgag406-B1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026101205065799800_dgag406-B2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2026101205065799800_dgag406-B3","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026101205065799800_dgag406-B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"2026101205065799800_dgag406-B5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2026101205065799800_dgag406-B6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101205065799800_dgag406-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","article-title":"Treatment of macroprolactinoma with cabergoline: a study of 85 patients","volume":"46","author":"Ferrari","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026101205065799800_dgag406-B8","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101205065799800_dgag406-B9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026101205065799800_dgag406-B10","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026101205065799800_dgag406-B11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026101205065799800_dgag406-B12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1009913200542","article-title":"Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas","volume":"2","author":"Pontikides","year":"2000","journal-title":"Pituitary"},{"issue":"5","key":"2026101205065799800_dgag406-B13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01137.x","article-title":"Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas","volume":"53","author":"George","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026101205065799800_dgag406-B14","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026101205065799800_dgag406-B15","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026101205065799800_dgag406-B16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026101205065799800_dgag406-B17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","article-title":"Pregnancy outcome after cabergoline treatment in early weeks of gestation","volume":"16","author":"Ricci","year":"2002","journal-title":"Reproductive Toxicology"},{"issue":"2","key":"2026101205065799800_dgag406-B18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1022364514971","article-title":"Medical management of pituitary adenomas: the special case of management of the pregnant woman","volume":"5","author":"Bronstein","year":"2002","journal-title":"Pituitary"},{"key":"2026101205065799800_dgag406-B19","first-page":"108","article-title":"Prolactin excess: treatment and toxicity","volume":"2 Suppl 1","author":"Gillam","year":"2004","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"2026101205065799800_dgag406-B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","article-title":"Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study","volume":"68","author":"Colao","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026101205065799800_dgag406-B21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00404-008-0917-8","article-title":"Pregnancy outcome in pituitary tumors","volume":"280","author":"Sharma","year":"2009","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2026101205065799800_dgag406-B22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026101205065799800_dgag406-B23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11102-010-0243-6","article-title":"Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature","volume":"13","author":"Stalldecker","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"2026101205065799800_dgag406-B24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","article-title":"Factors determining the remission of microprolactinomas after dopamine agonist withdrawal","volume":"72","author":"Huda","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026101205065799800_dgag406-B25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","article-title":"Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation","volume":"98","author":"Auriemma","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101205065799800_dgag406-B26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026101205065799800_dgag406-B27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/09513590.2016.1254177","article-title":"Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy","volume":"33","author":"Rastogi","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"2026101205065799800_dgag406-B28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AOG.0000000000001747","article-title":"Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes","volume":"129","author":"Lambert","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2026101205065799800_dgag406-B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40618-017-0709-8","article-title":"How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey","volume":"41","author":"Karaca","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026101205065799800_dgag406-B30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ajo.13070","article-title":"An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists","volume":"60","author":"O'Sullivan","year":"2020","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"2026101205065799800_dgag406-B31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/cen.14162","article-title":"Evolution of macroprolactinomas during pregnancy: a cohort study of 85 pregnancies","volume":"92","author":"Barraud","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026101205065799800_dgag406-B32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant\u2019 Anna","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"2026101205065799800_dgag406-B33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4103\/ijem.ijem_372_21","article-title":"Prolactinoma outcome after pregnancy and lactation: a cohort study","volume":"25","author":"Laway","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"key":"2026101205065799800_dgag406-B34","doi-asserted-by":"publisher","author":"Ono","DOI":"10.1093\/edrv\/32.supp.1"},{"issue":"4","key":"2026101205065799800_dgag406-B35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00004728-199207000-00004","article-title":"Volume of pituitary macroadenomas: assessment by MRI","volume":"16","author":"Lundin","year":"1992","journal-title":"J Comput Assist Tomogr"},{"issue":"4","key":"2026101205065799800_dgag406-B36","first-page":"610","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"issue":"7","key":"2026101205065799800_dgag406-B37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"2026101205065799800_dgag406-B38","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026101205065799800_dgag406-B39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"issue":"6","key":"2026101205065799800_dgag406-B40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J Clin Psychol"},{"issue":"2","key":"2026101205065799800_dgag406-B41","doi-asserted-by":"crossref","DOI":"10.1111\/jne.70141","article-title":"Dense sampling for mapping pituitary growth dynamics before, during, and after pregnancy","volume":"38","author":"Picci","year":"2026","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"2026101205065799800_dgag406-B42","first-page":"64","article-title":"Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment","volume":"39","author":"Din\u00e7","year":"1998","journal-title":"Acta Radiol"},{"issue":"3","key":"2026101205065799800_dgag406-B43","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026101205065799800_dgag406-B44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1227\/neu.0000000000002109","article-title":"Resection of the cavernous Sinus medial wall improves remission rate in functioning pituitary tumors: retrospective analysis of 248 consecutive cases","volume":"91","author":"Ishida","year":"2022","journal-title":"Neurosurgery"},{"issue":"1","key":"2026101205065799800_dgag406-B45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101205065799800_dgag406-B46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101205065799800_dgag406-B47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jc.2013-2254","article-title":"A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists","volume":"99","author":"Drake","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026101205065799800_dgag406-B48","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1210\/jc.2016-2224","article-title":"A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline","volume":"101","author":"Drake","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101205065799800_dgag406-B49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol"},{"issue":"6","key":"2026101205065799800_dgag406-B50","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026101205065799800_dgag406-B51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2026101205065799800_dgag406-B52","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026101205065799800_dgag406-B53","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026101205065799800_dgag406-B54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2026101205065799800_dgag406-B55","article-title":"Impulse control disorders in southern Iraqi patients medicated with cabergoline for prolactinoma","volume":"16","author":"Mohammad","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"2026101205065799800_dgag406-B56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","article-title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre","volume":"28","author":"Hamblin","year":"2025","journal-title":"Pituitary"},{"key":"2026101205065799800_dgag406-B57","article-title":"Impulse control disorders in Parkinson's disease: epidemiology, pathogenesis and therapeutic strategies","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Psychiatry"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag406\/71537526\/dgag406.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag406\/71537526\/dgag406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:07:10Z","timestamp":1791796030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag406\/8856754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag406","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"dgag406"}}